Rituximab response rates
| Type of transplantation . | Response rate . | Reference . |
|---|---|---|
| Cord | 5/9 | Brunstein et al45 |
| T cell–depleted HSCT | 3/3 | van Esser et al46 |
| Allogeneic HSCT | 3/3 | Kuehnle et al44 |
| Autologous CD34 selected HSCT | 4/5 | Powell et al47 |
| Solid organ transplantation | 6/6 | Savoldo et al48 |
| Solid organ transplantation | 7/8 | Ganne et al49 |
| Solid organ transplantation | 6/11 CR; 1/11 PR | Blaes et al50 |
| Solid organ transplantation | 9/17/ CR; 1/17 PR | Oertel et al51 |
| Solid organ transplantation | 19/43 | Choquet et al52 |
| Type of transplantation . | Response rate . | Reference . |
|---|---|---|
| Cord | 5/9 | Brunstein et al45 |
| T cell–depleted HSCT | 3/3 | van Esser et al46 |
| Allogeneic HSCT | 3/3 | Kuehnle et al44 |
| Autologous CD34 selected HSCT | 4/5 | Powell et al47 |
| Solid organ transplantation | 6/6 | Savoldo et al48 |
| Solid organ transplantation | 7/8 | Ganne et al49 |
| Solid organ transplantation | 6/11 CR; 1/11 PR | Blaes et al50 |
| Solid organ transplantation | 9/17/ CR; 1/17 PR | Oertel et al51 |
| Solid organ transplantation | 19/43 | Choquet et al52 |
Initial response rates to rituximab in several small trials in patients with PTLD after transplantation.
CR indicates complete response; and PR, partial response.